Item | Notes |
---|
OOOs | |
TB LWP: Issue Log | Published Link: https://app.smartsheet.com/b/publish?EQBCT=1136271a8d2e4fa184ebc0833df46742 Smartsheet: https://app.smartsheet.com/sheets/8q4pGFcfXc4mmgCw5Q4CQ43j93G6ChHCjxQ5pGm1 |
TB Testing Updates Target Deadlines | |
TB LWP: WGS & tNGS TRF Updates | Finalized TRF for review/development Updates identified 11/1/2023--Review in QC1”: Move “Phenotypic DST (pDST) is recommended to be performed in conjunction with sequencing-based DST, unless pDST has already been performed or will be conducted elsewhere. Please choose pDST test below (leave blank if not needed)” to appear as part of the Additional Test Option(s). Insert space b/w elsewhere and Please Update: Updated! Please choose a pDST test below (leave blank if not needed)” to appear as part of the Additional Test Option(s).
Logic Updated: Display ALL three test options, but apply condition logic: If First-line pDST (RIF, INH, PZA, EMB) is chosen, then First-line pDST for 4-month RPT-MOX regimen (RIF, INH, PZA, MOX) should be removed Second-line pDST (MOX, AMK, CAP, ETA, KAN, RFB) If First-line pDST for 4-month RPT-MOX regimen (RIF, INH, PZA, MOX) is chosen, then First-line pDST (RIF, INH, PZA, EMB) should be removed
All test options should be displayed if any material (sediment, culture, etc) is selected Update needed: If material selected is sediment, only 1 test option is displayed [First-line pDST for 4-month RPT-MOX regimen (RIF, INH, PZA, MOX)] Update needed: display all test options
Add title: “Additional Test Option” to each test option Please confirm that you would like TB DST Reference Center to perform WGS Genotyping * OPTION SHOULD be defaulted/auto-selected: Yes, please perform default testing Update: Has sequencing-based DST been performed by CDPH or CDC on a sample from this patient previously?
Update text: Phenotypic DST (pDST) WGS Genotyping
Submitting Lab Results Section: Update needed: Pop-up text should be changed to: "Sample should be sent to CDC for MDDR and not to MDL for sequencing-based DST" Change text “Indicate reason(s) for sequencing-based DST below, if applicable” to “Please select any that apply”
|
TB Mapping Documentation | |
11/8/23: Updates Identified: |
Additional TRF Changes | Changes to sediments/specimens: CDPH Proposed Updates: Modifications: Move “Sediment-AFB Negative” from “Other” to “Sediment”
a. if “Sediment-AFB Negative” selected: i. show selection “*Material approved by CDPH”: Yes/No AND ii. display message: Under “Other” add additional options:
a. Processed tissue b. Mixed culture c. Non-viable culture d. Other (add comment field, if selected) Rename “Other” to “Other (e.g. tissue, mixed culture)”
Need to discuss with APHL/CDC: Some of these proposed changes are not allowable sediments
If user selects Culture, maps to WGS panel Option: If user selects “Culture” AND IN Submitting Lab Results AOE the user selects Mixed Culture OR (and/or) Non-Viable Culture then the panel ordered should be to Add “M_TBDST_tNGS” Panel and “M_TBtNGS_Aux” Panel. Long-term: Would be good to capture and store this information discretely for tracking/auditing purposes (storing as comment tab would make it difficult to discretely parse) Next step:
|
Questions | |
Next Steps & Action Items | ICC: Provide current list of TB Specimen Sources and any associated mappings for review: 11/8 ICC: Olga will apply updates for review in QC1 APHL: ICC to provide summary of universal changes which may be applied to both MDL/VRDL AND TB LWPs for review to Steven/TB Team prior to applying to TB LWP so we have consensus and awareness of changes, potential impact, and historic documentation Next: CDPH/GG will review in QC1, identify any additional changes needed Sarah N Buss Will follow up with CDC to determine if additional specimen types/material type modifiers are allowable for testing (will determine development option if allowable) ICC/Catherine: Provide current list of TB Specimen Sources and any associated mappings for review: 11/8
|